Abliva AB (publ)
SSE:ABLI.ST
0.24 (SEK) • At close February 20, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Abliva AB (publ) |
Symbool | ABLI.ST |
Munteenheid | SEK |
Prijs | 0.238 |
Beurswaarde | 250,871,250 |
Dividendpercentage | 0% |
52-weken bereik | 0.19 - 0.316 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Ms. Catharina Jz Johansson |
Website | https://abliva.com |
An error occurred while fetching data.
Over Abliva AB (publ)
Abliva AB (publ) develops medicines for the treatment of primary mitochondrial diseases. The company is developing KL1333 that is in Phase 2/3 clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (SEK)
Cijfers zijn in miljoenen (SEK)